Abstract
Oxygenators are a lifesaving technology used for blood oxygenation and decarboxylation in case of acute respiratory failure, chronic lung disease, and during open-heart surgery. Devices typically consist of a bundle of thousands of fiber membranes in a housing, with gas flowing inside the fibers and blood flowing in the opposite direction outside the fibers. Both ends of the fiber membranes are attached with an adhesive to prevent direct contact between gas and blood. The shape of the volume through which the blood flows is determined by the housing of the oxygenator and the internal end surfaces of the bonded parts of the fiber-membrane bundle. The traditional potting process results in a volume shape that is associated with stagnation zones, which are known to promote thrombus formation. In this study, an adapted potting process is proposed which results in a blood compartment with beveled end faces of the glued bundle parts. Using a numerical study, we have demonstrated that the novel oxygenator design results in optimized flow conditions.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
